Biography for John Carroll
John D. Carroll, Editor-in-Chief
John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at email@example.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
Cambridge, MA-based Catabasis is once again raising cash. According to a Form D filed with the SEC yesterday, the biotech has raised $12.4 million out of a $20.4 million raise.
Back at the big JP Morgan conference in San Francisco in January, Roche's big $1 billion-plus tie-up with Foundation Medicine made it clear to the most casual biopharma observer that the pharma giant plans to partner more frequently as it builds up its pipeline and expands on its diagnostics business.
A big venture round led by Sofinnova Ventures and backed by a lengthy string of biotech stalwarts and public investment firms is bound to get tongues wagging again about a possible IPO in the near future for San Diego-based aTyr.
Hutchison China MediTech has met the primary endpoint of progression-free survival in a Phase II clinical trial for its metastatic colorectal cancer candidate fruquintinib (HMPL-013), putting it one step closer to an approval in China, according to FiercePharmaAsia.
Back in mid-January, CoLucid Pharmaceuticals raised about $37 million to back its Phase III study of a new migraine drug. A week ago the biotech said it had pulled up stakes in Durham, NC, and had temporarily located its HQ in Burlington, MA, as it searched for new offices in Cambridge. And now it has pulled back the covers on an $86 million IPO.
SR One, GlaxoSmithKline's venture arm, has joined a syndicate backing a big midstage study of a new kidney drug developed by Montreal-based Thrasos Therapeutics.
Are two breakthrough cancer drugs better than one? Pharma giant Merck and Waltham, MA-based Syndax plan to find out in a Phase Ib/II study matching the tiny biotech's entinostat with Keytruda, Merck's big anti-PD-1 therapy newly approved for melanoma.
Fujifilm has dipped into its multibillion-dollar cache of buyout cash for the $307 million it needed to acquire Cellular Dynamics International, one of the pioneers in the stem cell research business.
The small, Houston-based gene therapy company MultiVir has filed for a $70 million IPO with plans to advance its lead program for Ad-p53.